A Checklist for Selling a Life Sciences Consulting Firm

• Document which consulting output, reports, models, methodologies, is owned by your firm versus licensed or co-developed with a client under a specific engagement
• Confirm whether any principal consultants have outside conflicts, board seats, advisory roles, or equity positions, at client companies that a buyer needs to know about
• Check client contracts for confidentiality terms that might restrict how specifically you can describe engagements in a listing or teaser
• Identify how much revenue depends on one or two named scientific experts personally versus the firm's broader team and methodology
• Confirm your firm's data handling and any regulatory-adjacent compliance obligations, since biotech and pharma clients often impose their own vendor requirements
• Gather concrete, checkable proof of scientific credibility rather than relying on reputation alone

A buyer can't easily verify "deep credibility in the space" the way they can verify a contract or a bank statement. Back it up concretely: named publications, speaking engagements, repeat business from recognizable client types (described generally if confidentiality requires it), and any advisory board seats your principals hold. Vague credibility claims read as weaker than specific, checkable ones.

Build a one-page credibility summary before you list, the kind of document you'd hand a skeptical buyer in the first serious conversation. Founders who assemble this early consistently report smoother early conversations than those who try to build the case on the fly during a live call, when the specific details are harder to recall accurately.

Both Acquire.com and Flippa reach a broad, general buyer audience, and very few of those buyers will have the scientific background to evaluate a life sciences consulting practice on its merits. Expect longer sales cycles and more buyer education than a typical software or e-commerce listing, and don't be discouraged if serious interest takes longer to materialize than the platforms' own marketing suggests.

Build a short explainer document that translates your firm's value into terms a generalist buyer can evaluate quickly: client retention, revenue by engagement type, and margin, alongside the scientific credibility material. It shortens the gap between a buyer's first look and a serious conversation considerably.

Acquire.com's more technology-literate buyer pool includes some healthtech and biotech-adjacent strategic acquirers who understand the category noticeably better than a fully generalist audience would. Flippa's broader marketplace and brokered path for larger deals cast a wider net, useful if you're open to a buyer from outside the life sciences world specifically, such as a broader professional-services consolidator looking to add scientific depth to its portfolio.

Biotech and pharma clients frequently impose their own vendor compliance requirements, data handling standards, or audit rights, on top of whatever your firm carries independently. Confirm which of these obligations survive a change in ownership and whether a buyer would need to requalify with each client separately, since that can add real, meaningful time to a deal that a general marketplace listing simply won't anticipate for you.

The buyers best positioned to value a life sciences consulting practice, larger CROs, consultancies looking to add scientific depth, healthtech platforms, often aren't actively browsing a general marketplace at all. Identify a short list of realistic strategic acquirers yourself and consider a direct, confidential approach alongside any listing, rather than waiting entirely on inbound interest to find you.

A warm introduction through a mutual scientific advisory contact tends to open doors a cold listing never will in this world, so use your existing professional network deliberately as part of the process, not as an afterthought.

If your firm's value is inseparable from one or two named scientists' personal reputations, a buyer will structure a significant earnout around their continued involvement, and rightly so. If you want a fuller price at close instead, invest in building out named expertise across more of your team well before you list, not during negotiations when a buyer already has the upper hand.